title: Prolonged follow-up period following intravitreal bevacizumab injection for stage 3+ retinopathy of prematurity.
authors.affiliation: Department of Ophthalmology, Manchester Royal Eye Hospital, Manchester, UK.
authors.forename: T A
authors.initials: TA
authors.lastname: de Klerk
authors.forename: D Y
authors.initials: DY
authors.lastname: Park
authors.forename: S
authors.initials: S
authors.lastname: Biswas
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D058449:Intravitreal Injections; D012178:Retinopathy of Prematurity / Q000188:drug therapy*; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab